Medical Device Supply Chains Face Rising Plastic Dependency Risks
Medical device manufacturers face a growing supply chain vulnerability due to their heavy reliance on virgin, fossil fuel-derived plastics, a risk that procurement strategies frequently overlook. Research published in Breaking the Plastic Wave 2025—produced by The Pew Charitable Trust alongside the Ellen MacArthur Foundation, Imperial College London, Systemiq and the University of Oxford—indicates that industrial plastic use will surge by over 50% by 2040 without substantial intervention.
Complex, international supply chains that provide medical device polymers remain vulnerable to ongoing disruptions. Causes range from the pandemic and cyberattacks to geopolitical instability and extreme weather, as highlighted in the OECD Supply Chain Resilience Review. Material dependency has transformed into a long-term business risk, threatening the commercialization of safe and affordable devices.
Regulatory Hurdles Limit Alternative Bioplastics
Switching to alternative materials presents substantial obstacles for medical device manufacturers.
Bio-based polymers typically cost 50% to 100% more than fossil fuel-based plastics due to fluctuating feedstock costs and smaller production scales. European Bioplastics data indicates that global bioplastic production capacity represents approximately 0.5% of total annual plastic production. While gloves, drapes, and staplers utilize bioplastics, safety and durability concerns hinder their adoption in injection devices.
Reprocessing Offers Resilient Alternatives to Recycling
To reduce virgin material dependency, manufacturers increasingly evaluate circular strategies. While recycling programs recover base polymers, they often result in downcycling that destroys the value added during precision molding and assembly.
By contrast, reprocessing and remanufacturing preserve significantly more technical and commercial value. The U.S. reprocessing sector, regulated by the Food and Drug Administration, demonstrates practical impact through the Association of Medical Device Reprocessors (AMDR). Figures compiled by the AMDR reveal that across 18 nations during 2025, 11,458 hospitals and surgical facilities purchased upwards of 39.3 million regulated, reprocessed single-use devices, yielding in excess of $449.5 million in recorded savings for medical facilities while cutting CO2-equivalent emissions by more than 125 million pounds.
Common Questions About Medical Device Circularity
How does medical device reprocessing work in practice?
Reprocessing involves the cleaning, disinfection, and sterilization of used single-use devices, alongside restoring their technical and functional safety for clinical use.
What financial impact does medical device reprocessing deliver?
Data from the Association of Medical Device Reprocessors indicates that reprocessed single-use devices generated more than $449.5 million in documented hospital savings across 18 countries in 2025.
“Circularity decouples growth from resource consumption. For a manufacturer, that is strategic freedom: serving more patients without exposure to fragile supply chains and volatile commodities markets,” said Cedric Gysel, CEO of Be Circular.
Keep reading